Table 2.

Effect of HLE-FP on relative organ weight in the sub-chronic oral toxicity study.

Group	30 days treatment						60 days treatment						Reversibility study
	Liver	Stomach	Lungs	Spleen	Kidneys	Heart	Liver	Stomach	Lungs	Spleen	Kidneys	Heart	Liver	Stomach	Lungs	Spleen	Kidneys	Heart
I	3.40 ± 0.48	1.32 ± 0.23	0.89 ± 0.23	0.66 ± 0.11	0.66 ± 0.11	0.66 ± 0.11	4.18 ± 1.05	1.31 ± 0.29	0.96 ± 0.35	0.59 ± 0.04	0.59± 0.04	0.59 ± 0.04	2.91± 0.24	1.08 ± 0.12	1.08 ± 0.37	0.54± 0.06	0.54 ± 0.06	0.54± 0.06
II	4.01± 0.37	3.80 ± 1.27	0.89 ± 0.40	0.72 ± 0.08	0.72 ± 0.11	0.72 ± 0.11	3.71 ± 0.79	1.31 ± 0.29	1.90 ± 0.92	0.64 ± 0.02	0.64 ± 0.02	0.64 ± 0.02	2.70 ± 0.20	1.05 ± 0.08	1.05 ± 0.08	0.53 ± 0.04	0.53 ± 0.04	0.53 ± 0.04
III	4.21 ± 0.34	3.74 ± 0.50	1.10 ± 0.48	0.84 ± 0.29	0.84 ± 0.29	0.84 ± 0.29	3.66 ± 0.31	1.54 ± 0.28	1.19 ± 0.09	1.19 ± 0.49	1.19 ± 0.49	1.19 ± 0.49	3.26 ± 0.29	1.05 ± 0.32	1.14 ± 0.33	0.53 ± 0.06	0.53 ± 0.06	0.53 ± 0.06
IV	3.49 ± 0.29	1.29 ± 0.03	0.64 ± 0.01	0.65 ± 0.01	0.65 ± 0.01	0.65 ± 0.01	3.85 ± 0.21	1.20 ± 0.04	0.84 ± 0.27	1.21 ± 0.50	1.21 ± 0.50	1.21 ± 0.50	3.54 ± 0.25	1.15 ± 0.13	1.20 ± 0.24	0.58 ± 0.06	0.58 ± 0.06	0.58 ± 0.06

p > 0.05 compared to control values (Group IV).

I, 500 mg/kg/day HLE-FP; II, 100 mg/kg/day HLE-FP; III, 20 mg/kg/day HLE-FP; IV, 10 ml/kg normal saline.